First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies
机构：[1]Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin, China[2]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[3]The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China[4]Affiliated hospital of Hebei University, Baoding, China河北大学附属医院[5]Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX[6]Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY[7]The First Affiliated Hospital of Bengbu Medical Collegue, Bengbu, China[8]GenFleet Therapeutics, Shanghai, China[9]Sellas Life Sciences Group, New York, NY
第一作者机构：[1]Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin, China
推荐引用方式(GB/T 7714)：
Qi Junyuan,Zhou Keshu,Qian Wenbin,et al.First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies[J].BLOOD.2022,140:9473-9474.doi:10.1182/blood-2022-159844.
APA：
Qi, Junyuan,Zhou, Keshu,Qian, Wenbin,Zang, Aimin,Kadia, Tapan M....&Wang, Jianxiang.(2022).First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies.BLOOD,140,
MLA：
Qi, Junyuan,et al."First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies".BLOOD 140.(2022):9473-9474
医学